Dianthus Therapeutics Inc (DNTH) - News Archive

Dianthus Therapeutics Inc. (NASDAQ: DNTH), a promising player in the biopharmaceutical sector, is gearing up to participate in three significant healthcare investor conferences this September. As the company continues t...

Multifocal Motor Neuropathy (MMN) is a debilitating neurological disorder characterized by muscle weakness and atrophy, resulting from damage to the motor nerves. Despite being a rare condition, the impact on patients q...

In a recent press release, Dianthus Therapeutics, a renowned clinical-stage biotechnology company focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases, announced the gran...

Dianthus Therapeutics, a renowned clinical-stage biotechnology company, recently unveiled promising research findings on their antibody complement therapeutic, DNTH103, at the American Academy of Neurology (AAN) Annual...

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Dianthus Therapeutics, Inc. (Dianthus), a clinical-stage biotechnology company specializing in antibody complement therapeutics for s...

Dianthus Therapeutics: Securing $230 Million Private Placement to Advance Autoimmune Disease TreatmentsIn a major financial development, Dianthus Therapeutics, Inc. announced today that it has successfully entered into...